Mirum Pharmaceuticals: Specialist in Rare Liver Diseases with 4 Billion USD Opportunity!
Reading Time: 3 minutes
Mirum Pharmaceuticals is transforming from its main product LIVMARLI into a diversified specialty pharmaceutical company for rare genetic diseases. The pipeline offers a revenue opportunity of over 4 billion USD. Phase 2 data for Zilurgisertib, along with primary endpoints for Volixibat and Brelovitug, underpin long-term expansion plans. The first quarter showed impressive growth with a revenue increase of over 43%. The annual forecast has been raised to between 660 and 680 million USD, an increase of up to 30%. Mirum Pharmaceuticals...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
